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Clinical studies have demonstrated that HLA-DPB1emismatched allogeneic stem cell transplantation (allo-
SCT) is associated with a decreased risk of disease relapse and an increased risk of graft-versus-host disease
(GVHD) compared with HLA-DPB1ematched SCT. In T celledepleted allo-SCT, mismatching of HLA-DPB1 was
not associated with an increased risk of severe GVHD, but a signiﬁcant decreased risk of disease relapse was
still observed. To investigate whether patient HLA-DPespeciﬁc CD4þ T cell responses were frequently induced
after T celledepleted HLA-DPB1emismatched allo-SCT and donor lymphocyte infusion (DLI), we developed
a method to screen for the presence of HLA-DPespeciﬁc CD4þ T cells using CD137 as an activation marker and
analyzed 24 patientedonor combinations. The patients suffered from various B cell malignancies, multiple
myeloma, and myeloid leukemias. Patient HLA-DPespeciﬁc CD4þ T cells were detected after DLI in 13 of 18
patients who exhibited a clinical response to DLI, compared with only 1 of 6 patients without a clinical
response to DLI. Eight patients developed signiﬁcant GVHD. These data show that patient HLA-DPespeciﬁc
CD4þ T cells frequently occur after HLA-DPB1emismatched T celledepleted allo-SCT and DLI, and are asso-
ciated with graft-versus-leukemia reactivity both in the presence and absence of GVHD.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION allo-SCT [14,15]. We previously demonstrated a profound GVL
After allogeneic hematopoietic stem cell transplantation
(allo-SCT), donor-derived T cells recognizing mismatched
antigens on residual malignant cells can induce strong graft-
versus-leukemia (GVL) reactions. Treatment of patients with
relapsed leukemia, lymphoma, or multiple myeloma with
allo-SCT followed by donor lymphocyte infusion (DLI) can
result in long-lasting complete remission [1-6]. Unfortu-
nately, the beneﬁcial GVL effects of DLI are often accompa-
nied by graft-versus-host disease (GVHD). To reduce the risk
of GVHD, patients and donors are preferably matched for
HLA-A, -B, -C, -DRB1, and -DQB1 (8/8 or 10/10 match) [7-9].
HLA-DPB1 is often not taken into consideration in donor
selection, since the overall mortality of patients who under-
went HLA-DPB1ematched or emismatched allo-SCT did not
statistically differ. However, HLA-DPB1 matching status did
have an impact on GVL reactivity and GVHD [8,10-13]. In
T celledepleted allo-SCT, mismatching for HLA-DPB1 has
been associated with a signiﬁcant decreased risk of disease
relapse with no increased risk of severe GVHD [11]. The role of
HLA-DP as a transplantation antigen was conﬁrmed by the
isolation of polyclonal HLA-DPespeciﬁc CD4þ Tcells from skin
biopsies of patients with GVHD after HLA-DPB1emismatchededgments on page 48.
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12.07.020effect with only minimal skin GVHD caused by polyclonal
HLA-DPespeciﬁc CD4þ T cells in a patient responding to
HLA-DPB1emismatched DLI for refractory chronic B cell
leukemia, suggesting thatHLA-DPespeciﬁc CD4þ Tcells can be
involved in GVHD, as well as in selective GVL reactivity [5].
The beneﬁcial effect of mismatching for HLA-DPB1 in
Tcelledepleted allo-SCTon disease relapse has been reported
to be more pronounced in patients with acute lymphoblastic
leukemia compared with those with myeloid leukemias
[16].HighexpressionofHLAclass IImolecules, includingHLA-
DP, is found in most B acute lymphoblastic leukemia and B
chronic lymphocytic leukemia cells, whereas myeloid
leukemic cells show more variable expression of HLA-DP.
However, HLA-DPeexpressing myeloid leukemic cells
have been demonstrated to be recognized and lysed by
HLA-DPespeciﬁc CD4þ T cells [5,17]. Thus, both B cell and
myeloid hematologic malignancies with sufﬁcient HLA-DP
expression may be susceptible to an HLA-DPemediated
GVL effect.
The aim of the present study was to investigate whether
HLA-DPespeciﬁc CD4þ T cell responses frequently occur
after HLA-DPB1emismatched allo-SCT and DLI, and whe-
ther the development of patient HLA-DPespeciﬁc CD4þ
T cell responses was associated with beneﬁcial clinical
responses (ie, GVL effect) or GVHD. We therefore analyzed
HLA-DPespeciﬁc immune responses and clinical responses
in 24 patients treated with DLI after 10/10-matched,
HLA-DPB1emismatched T celledepleted allo-SCT.Transplantation.
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DPespeciﬁc immune response after DLI administration, we
developed an assay to screen for allogeneic HLA-DPespeciﬁc
CD4þ Tcells. In this assay, weusedHLA class IIenegativeHeLa
cells transduced with all molecules relevant for HLA class II
processing as stimulator cells and transduced patient- or
donor-speciﬁc HLA-DP molecules into these cells to measure
the emergence of patient HLA-DPespeciﬁc CD4þ T cells in
peripheral blood (PB). Using these HLA-DPe transducedHeLa
cells, we introduced patient and donor HLA-DPB1 molecules
as single variables to detect HLA-DPespeciﬁc immune
responses. Patient HLA-DPespeciﬁc CD4þ T cells were found
in 72% of the patients who demonstrated a clinical response
after DLI, but only in 1 of 6 patients (17%) without a clinical
response to DLI. Patient HLA-DPespeciﬁc CD4þ T cells were
found in patients with GVHD and in patients with selective
GVL reactivity without GVHD. HLA-DPespeciﬁc CD4þ T cell
responses were observed in patients suffering from B cell
malignancies, multiple myeloma, and myeloid leukemias.
MATERIALS AND METHODS
Cell Collection and Preparation
PB samples were obtained from patients and healthy stem cell donors
after approval by Leiden University Medical Center’s Institutional Review
Board and provision of informed consent in accordance with the Declaration
of Helsinki. Samples were collected during standard follow-up after allo-SCT
and DLI (ie, 6 weeks, 3 months and 6months). In some individuals, additional
samples were available. PB mononuclear cells (PBMNCs) were isolated by
Ficoll-Isopaque separation and cryopreserved. Stable Epstein-Barr virus
(EBV)-transformed B cell lines were generated using standard procedures.
EBV lymphoblastic cell lines (LCLs) and HeLa cells were cultured in Iscove’s
modiﬁed Dulbecco’s Medium (IMDM; BioWhittaker, Verviers, Belgium) sup-
plemented with 10% FBS (BioWhittaker).
Patient Selection and Characteristics
The study included a total of 24 patients who underwent a 10/10-
matched, HLA-DPB1emismatched T celledepleted allo-SCT followed by DLI
between 2000 and 2008 (Table 1). The patients suffered from multiple
myeloma (n¼ 8), B cell malignancies (n¼ 7), and myeloid leukemias (n ¼ 9).
Fifteen patients received a single DLI, and 9 patients received 2 or more DLIs.
Indications for DLI included mixed chimerism, persistent or progressive
disease, and EBV posttransplantation lymphoproliferative disorder. Leukocyte
chimerism in bone marrow was determined by short tandem repeat analysis.
In the absence of relapse or GVHD, the level of mixed chimerismwas stable in
the ﬁrst months after allo-SCT. DLI was administered on an intention-to-treat
basis in accordance with standard protocols. The ﬁrst DLI was given between
4 months and 26 months after allo-SCT. At 4 months, 0.15*10e6 CD3þ T cells
were administered. At 6 months, 1.5*10e6 CD3þ T cells were given for mixed
chimerism or persistent disease, and 2.5*10e6 CD3þ T cells were given for
progressive disease. At 9 months, 2.5*10e6 CD3þ T cells were administered.
Dose escalation to a maximum of 5*10e7 CD3þ T cells was provided to
patients receiving subsequent DLIs. The ﬁrst DLI was freshly harvested, and
cryopreserved material was used for subsequent DLIs.
Flow Cytometry
The monoclonal antibodies (mAbs) antieCD3 ﬂuorescein isothiocyanate
(FITC), antienerve growth factor receptor phycoerythrin (PE), antieCD4
peridinin chlorophyll protein (PerCP), anti-CD137 allophycocyanin (APC),
and antieIFN-g APC were obtained from BD Biosciences (San Jose, CA). Anti-
CD154-PE was obtained from Beckman Coulter (Fullerton, CA). AntieHLA-
DP-PE mAbs were purchased from Leinco Technologies (St. Louis, MO).
Flow cytometry analysis was performed on a BD ﬂow cytometer, and cell
sorting was done with a BD FACSAria cell-sorting system.
Transduction with Different HLA-DP Constructs
HeLa cells and EBV-LCLs were transduced with different HLA-DPA1 and
HLA-DPB1 molecules as described previously [18]. In brief, HeLa cells were
transduced with CD80, HLA-DM, and invariant chain (HeLa-II cells) to allow
appropriate co-stimulation and processing of HLA-DP molecules. Puriﬁed
HeLa-II cells were then transduced with different combinations of HLA-
DPA1 and HLA-DPB1 molecules and selected based on positive staining with
antieHLA-DP-PE antibodies. HLA-DPetransduced EBV-LCLs were selected
based on marker gene expression.Characterization of HLA-DPeSpeciﬁc CD4þ T Cells in PBMNCs
To validate the use of HLA-DPetransduced HeLa-II cells as stimulator
cells to detect HLA-DPespeciﬁc CD4þ T cells in PB, we used PBMNCs from
a patient in whom we previously demonstrated a profound HLA-
DPB1*03:01especiﬁc immune response. To determine the optimal method
for detecting HLA-DPespeciﬁc CD4þ T cells, we compared percentages of
activated CD4þ T cells using different activation markers after various
incubation periods. Cryopreserved PBMNCs were thawed, and CD4þ T cells
were positively selected using magnetic CD4 beads (Miltenyi Biotec,
Bergisch Gladbach, Germany) in accordance with the manufacturer’s
instructions. Then 0.1  10e6 puriﬁed CD4þ T cells were stimulated with
0.03  10e6 control HeLa-II cells or HeLa-II cells transduced with patient
HLA-DPB1*03:01 or donor HLA-DPB1*04:02 for 6-44 hours in 150 mL of
culture medium supplemented with 10% human serum and 10 IU/mL of IL-2
(Chiron, Amsterdam, the Netherlands).
For intracellular IFN-g and CD154 staining, cells were incubated in the
presence of 10 mg/mL of Brefeldin-A (Sigma-Aldrich, St. Louis, MO); harvested
after 6,10, or 18 hours of incubation; surface-stainedwith CD4-FITCe and CD3-
PerCPelabeled mAbs, ﬁxed with 1% paraformaldehyde; and permeabilized
using0.1%Saponin (Sigma-Aldrich). Thencellswere stained intracellularlywith
CD154-PEe and IFN-g APCelabeledmAbs and analyzed by ﬂow cytometry.
To determine the expression of surface CD154 and CD137, cells were
harvested after 16, 22, or 44 hours of incubation; washed; surface-stained
with CD4-FITCe, CD3-PerCPe, CD154-PEe, and CD137-APCelabeled mAbs;
and analyzed.
To conﬁrm speciﬁcity of CD137-expressing CD4þ T cells, 0.75  10e6
puriﬁed CD4þ T cells were stimulated with 0.15  10e6 HLA-
DPB1*03:01etransduced HeLa-II cells, and after 44 hours of incubation,
CD137-expressing CD4þ T cells were sorted single cell per well into
U-bottom microtiter plates. Proliferating CD4þ T cell clones were expanded
using nonspeciﬁc stimulation and third-party feeder cells. IFN-g production
in response to HLA-DPB1*03:01e or HLA-DPB1*04:02etransduced HeLa-II
cells, donor EBV-LCLs, or HLA-DPB1*03:01eexpressing EBV-LCLs was tested.
To determine IFN-g production, 5000 CD4þ T cells were co-cultured with
30,000 stimulator cells in 150 mL of medium. After overnight incubation,
supernatants were harvested, and IFN-g production was measured by ELISA
(CLB, Amsterdam, the Netherlands).Analysis of HLA-DPeSpeciﬁc CD4þ T Cells after Allo-SCT and DLI in 24
Patients
To quantify the presence of HLA-DPespeciﬁc CD4þ T cells in PBMNC, we
analyzed CD4þ T cells, derived from donors and from patients after allo-SCT
both before and after DLI, for CD137 expression in response to stimulation
with patient or donor HLA-DPB1 molecules. Samples obtained between 6
weeks and 6 months after DLI were analyzed according to availability and
moment of clinical response. CD4þ T cells were positively selected from
PBMNCs using magnetic CD4 beads (Miltenyi Biotec) in accordance with the
manufacturer’s instructions. A total of 0.15  10e6 CD4þ T cells were stim-
ulated with 0.03 10e6 HeLa-II cells, HeLa-II cells transduced with donor or
shared HLA-DPB1 molecules, or HeLa-II cells transduced with patient-
speciﬁc HLA-DPB1 molecules in 150 mL of IMDM supplemented with 10%
human serum and 10 IU/mL of IL-2. After 44 hours of incubation, CD137
expression on CD3þ/CD4þ T cells was analyzed by ﬂow cytometry.Clinical Responses after HLA-DPB1eMismatched T CelleDepleted Allo-
SCT and DLI
Clinical responses to DLI were deﬁned as beneﬁcial clinical responses or
GVHD. Beneﬁcial clinical responses were deﬁned as a sustained increase in
donor chimerism to 99% donor cells, or a decrease in malignant cells or
diseasemarkers resulting in either complete disappearance or a reduction of
>90%. Clinically important GVHD was considered present in case of acute
GVHD (aGVHD) grade II or greater or extensive chronic GVHD (cGVHD).
aGVHD was graded according to the Glucksberg criteria. cGVHD was graded
according to the Shulman criteria. Lesions of themouthmatching criteria for
cGVHD in the absence of other signs of cGVHD were classiﬁed as limited
cGVHD. Clinical datawere analyzed by a hematologist whowas not informed
of the presence or absence of HLA-DPespeciﬁc CD4þ T cells.Statistical Analysis
The association between the presence of patient HLA-DPespeciﬁc CD4þ
T cells and clinical responses was assessed using the 2-tailed Fisher exact
test. The Student t test after logarithmic transformationwas used to evaluate
for a statistically signiﬁcant difference inmagnitude betweenTcell responses
directed against permissive mismatches and those directed against nonper-
missive mismatches.
Table 1
Patient Characteristics
Patient Disease DLI (Months
after allo-SCT)
Indication for DLI HLA-DPeSpeciﬁc
T CD4þ T Cells, %
GVL/GVM aGVHD
(Weeks after DLI)
cGVHD (Months
after DLI)
Treatment
for GVHD
Treatment before DLI Remarks
1 Multiple myeloma 9 Persistent disease 0.30 Yes Grade III (2) No Systemic Thalidomide Deceased 2 months after DLI due to GVHD
2 Multiple myeloma 9 Mixed chimerism 0.29 Yes Grade I (9) Extensive* Systemic
3 Multiple myeloma 2 EBV-PTLD 0.17 Yes Grade IV (5) Extensive* Systemic R-CHOP for PTLD Measured during prednisone treatment
for PTLD
4 Multiple myeloma 9 Persistent disease 0.43 Yes Grade I (13) Extensive* Systemic
5 MCL 4 Mixed chimerism 0.16/0.25 Yes Grade II (13) No Systemic
6 CLL 10 Progressive disease 4.50 NIy Grade IV (5) No Systemic R-CHOP and radiotherapy Deceased 2 months after DLI due to
pulmonary distress, possibly GVHD/BOOP
7 Multiple myeloma 9 Progressive disease 0.84/0.19 No Grade II (6) Extensive* Systemic Radiotherapy
36 Progressive disease No No No No
8 AML 8 Mixed chimerism 0.15 No Grade I (12) Extensive* Systemic
9 CML 10 Molecular relapse 0.31 Yes No No
10 AML 4 Mixed chimersm 0.21 Yes No No
11 WM 7 Persistent disease 3.08/0.92 Yes Grade I (11) No Local
12 CML 26 Molecular relapse 0.17 Yes No No
13 AML 10 Mixed chimerism 0.19 No Grade I (9) No Local
28 Mixed chimerism No No No No
36 Mixed chimerism 0.15 Yes No No
14 Multiple myeloma 4 Persistent disease No No No No
11 Persistent disease No No No Bortezomib
18 Progressive disease No No Thalidomide
23 Progressive disease No No Lenalidomide
29 Progressive disease No Yes Grade I (9) No Local Cyclophosphamide +
prednisone + Lenalidomide
IFN-az
15 NHL 15 Mixed chimerism No No No No Rituximab 4 + prednisone For AIHA and thrombocytopenia
19 Mixed chimerism No Yes No No
16 CML 15 Molecular relapse No Yes No Limited (7) Local
17 CML 15 Cytogenetic relapse No No No No
20 Cytogenetic relapse No Yes Grade I (9) No No IFN-az
61 Cytogenetic relapse No No No No IFN-az
75 Cytogenetic relapse No Latex No No
18 CML 20 Molecular relapse No Yes No No
43 Molecular relapse No No No No
49 Molecular relapse No No No No
Lymphocyte
blast crisis
53 Progressive disease No No No Limited (6) No Polychemotherapy + Imatinib IFN-az
19 NHL 10 Mixed chimerism No No No No
16 Mixed chimerism No No No No
20 B-ALL 6 Mixed chimerism No No No Limited (6) Local
21 Multiple myeloma 6 Persistent disease No No No No
14 Persistent disease No No No No
22 Multiple myeloma 6 Mixed chimerism No No No No
23 MDS/AML 7 Progressive disease No No No No IFN-az
10 Progressive disease No No No No
24 NHL 8 Progressive disease 0.36 No No Limited (3) Local Rituximab Deceased 4 months after DLI due to
progressive disease
AIHA indicates autoimmune hemolytic anemia; AML, acute myeloid leukemia; B-ALL, B cell acute lymphoblastic leukemia; BOOP, bronchiolitis obliterans with organizing pneumonia; CLL, chronic lymphocytic leukemia; CML,
chronic myeloid leukemia; GVM, graft-versus-myeloma; MCL, mantle cell lymphoma; MDS, myelodysplastic syndrome; NHL, non-Hodgkin lymphoma; R-CHOP, rituximab + cyclophosphamide + doxorubicin + vincristine +
prednisolone; WM, Waldenstrom macroglobulinemia.
* aGVHD followed by cGVHD.
y Not interpretable; patient died from multiorgan failure before follow-up analysis was performed.
z IFN-a given at time of DLI to enhance immune response.
x Response observed >6 months after DLI.
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Detection and Isolation of HLA-DPeSpeciﬁc T Cells
To allow quantitative analysis of patient-speciﬁc alloge-
neic HLA-DP responses in patients treated with HLA-
DPB1emismatched T celledepleted allo-SCT and DLI, we
developed a method to screen for patient HLA-DPespeciﬁc
CD4þ T cells in PB using HLA class IIenegative HeLa cells
transduced with all molecules relevant for HLA class II pro-
cessing and different HLA-DP molecules as stimulator cells.
Transduction of the same stimulator cells with patient- or
donor-speciﬁc HLA-DP molecules as single variables allowed
detailed analysis of patient HLA-DPespeciﬁc CD4þ T cell
responses.
To validate the use of HLA-DPetransduced HeLa-II cells
as stimulator cells to detect HLA-DPespeciﬁc CD4þ T cells
in PB, we used PBMNCs from a patient in whom we
previously demonstrated a profound HLA-DPB1*03:01e
speciﬁc CD4þ T cell response. This patient underwent a
10/10-matched, HLA-DPB1emismatched allo-SCT followed
by DLI for relapsed chronic B cell leukemia [5]. Puriﬁed
CD4þ T cells isolated from PBMNCs from the peak of the
immune response at 14 weeks after DLI were stimulated
with HeLa-II cells transduced with patient HLA-DPB1*03:01
or donor HLA-DPB1*04:02. We compared the percentages
of activated CD4þ T cells using different markers after
various incubation periods. We found speciﬁc activation of
CD4þ T cells after stimulation with HeLa-II cells transduced
with patient HLA-DPB1*03:01 but not with donor HLA-
DPB1*04:02, indicating that HLA-DPetransduced HeLa-II
cells can be used as stimulator cells to detect allo-HLA-
DPespeciﬁc CD4þ T cells (Figure 1). Upon stimulation
with patient HLA-DPB1*03:01, maximum intracellular IFN-g
and CD154 staining was found after overnight incubation
showing 0.84% and 1.28% activated CD4þ T cells, respec-
tively. Stimulation with donor-speciﬁc HLA-DPB1*04:02 did
not result in activated CD4þ T cells compared with
background staining (0.12% for both IFN-g and CD154
expression) (Figure 1A). After stimulation with patient HLA-
DPB1*03:01, maximum surface CD137 or CD154 expression
was detected after 44 hours of incubation, resulting in
4.36% and 3.92% activated CD4þ T cells, respectively. Stim-
ulation with donor HLA-DPB1*04:02 resulted in only
background CD137 (0.07%) and CD154 (0.20%) expression
(Figure 1B).
We repeated the analysis of CD137 expression after
different incubation times in independent experiments and
found similar results (Figure 1C). Based on these results and
the favorable kinetics of CD137 expression on CD4þ T cells
shown by us and others [19-21], we selected CD137 as an
activation marker for further experiments.
To conﬁrm the speciﬁcity of CD137-expressing CD4þ
T cells for patient HLA-DPB1*03:01, we clonally isolated
CD137þ/CD4þ T cells by ﬂow cytometry and tested growing
T cell clones for speciﬁc recognition of HLA-DPB1*03:01. A
total of 46 CD4þ T cell clones were expanded, 41 (89%) of
which demonstrated speciﬁc recognition of both HeLa-II
cells transduced with HLA-DPB1*03:01 and EBV-LCLs
with endogenous HLA-DPB1*03:01 expression. In contrast,
HeLa-II cells transduced with donor HLA-DPB1*04:02 and
EBV-LCLs with endogenous HLA-DPB1*04:02 were not
recognized. These results conﬁrmed the speciﬁcity of CD137-
expressing CD4þ T cells for the allo-HLA-DPB1*03:01 mole-
cule, and also conﬁrmed that this method can be used to
measure HLA-DPespeciﬁc CD4þ T cells directly ex vivo.Patient HLA-DPeSpeciﬁc CD4þ T Cells Are Frequently
Detected after T CelleDepleted HLA-DPB1eMismatched
Allo-SCT and DLI
To analyze the presence of HLA-DPespeciﬁc CD4þ T cell
responses after HLA-DPB1 mismatched allo-SCT and DLI, we
analyzed immune responses in 24 patientswho had undergone
T celledepleted HLA-A, -B, -C, -DRB1, and -DQB1ematched,
HLA-DPB1emismatched allo-SCT. The patients received DLI
for various indications, including mixed chimerism and persis-
tent or progressive disease (Table 1). CD4þ Tcellswere obtained
from donors and from patients after allo-SCT before and after
DLI. For each patientedonor combination, puriﬁed CD4þ Tcells
were stimulatedwith controlHeLa-II cells andwithHeLa-II cells
transducedwithdonor-speciﬁc, shared, orpatient-speciﬁcHLA-
DPB1molecules. After 44hoursof incubation, CD137expression
on CD4þ T cells was measured.
Figure 2 shows a representative example of the analysis of
HLA-DPespeciﬁc CD4þ T cells in a patient with multiple
myelomawho had a clinical response to DLI. This patient was
typed HLA-DPB1*01:01,04:01, and the donor was typed
HLA-DPB1*04:01,05:01. The patient received a single dose of
2.5  10e6 CD3þ T cells for mixed chimerism at 9 months
after allo-SCT, resulting in conversion to 100% donor
chimerism 3 months later (Figure 2A). Stimulation of donor-
derived CD4þ T cells or CD4þ T cells derived from the patient
after allo-SCT before DLI with HeLa-II cells transduced with
donor HLA-DPB1*05:01, shared HLA-DPB1*04:01, or patient-
speciﬁc HLA-DPB1*01:01 molecules did not result in signif-
icant CD137 expression (0.01%-0.07%). However, CD4þ T cells
obtained 6 weeks after DLI showed 0.3% CD137þ/CD4þ T cells
on stimulation with patient HLA-DPB1*01:01, but no
increase in CD137þ/CD4þ T cells in response to shared or
donor-speciﬁc HLA-DPB1 molecules (Figure 2B). These
results illustrate the emergence of HLA-DPB1*01:01especiﬁc
CD4þ T cells in this patient 6 weeks after DLI.
Using this method, we screened the 24 patients for the
presence of patient HLA-DPespeciﬁc CD4þ T cell responses.
HLA-DPespeciﬁc immune responses were deﬁned as detec-
tion of >0.15% CD137þ/CD4þ T cells after stimulation with
HeLa-II cells transduced with patient-speciﬁc HLA-DPB1
molecules but not in response to donor or shared HLA-DPB1
molecules. A cutoff of 0.15%was deﬁned as a positive response
basedonbackgroundCD137expression in response toHeLa-II
cells or HeLa-II cells transduced with donor HLA-DPB1
molecules of <0.10% in all cases. Nine of the 24 patients
exhibited 2 patient-speciﬁc HLA-DPB1 alleles different from
the donor; the other 15 patients had only 1 patient-speciﬁc
HLA-DPB1 allele. Figure 3 shows the percentages of CD137þ/
CD4þ T cells in these 24 patients in response to stimulation
with the 33 patient-speciﬁc HLA-DPB1 molecules and 39
donor-speciﬁc or shared HLA-DPB1 molecules evaluated.
In 14 patients, patient HLA-DPespeciﬁc CD4þ T cells were
detected after DLI. Speciﬁc CD137þ/CD4þ T cells varying from
0.15% to 4.5% were measured after stimulation with HeLa-II
cells transducedwith patient HLA-DPB1molecules but not in
response to donor HLA-DPB1, including shared HLA-DPB1
molecules (0-0.07%). Patient HLA-DPespeciﬁc CD4þ T cells
were measured in 9 of the 15 patients with a single
HLA-DPB1 mismatch and in 5 of the 9 patients with 2
HLA-DPB1mismatches. Three of the latter 5 patients showed
CD4þ T cell responses to both mismatched HLA-DPB1 alleles.
In 12 of the 14 patients with detectable HLA-DPespeciﬁc
CD4þ T cells, patient HLA-DPespeciﬁc immune responses
were likely to be induced by DLI, since no CD137þ/CD4þ T
Figure 1. Kinetics of different activation markers for detecting patient HLA-DPespeciﬁc CD4þ T cells directly ex vivo. PBMNCs from a patient (HLA-DPB1*02:01,03:01)
who underwent allo-SCT for chronic B cell leukemia with an HLA-DPB1emismatched donor (HLA-DPB1*04:02,05:01) were analyzed for the presence of HLA-
DPB1*03:01especiﬁc CD4þ T cells. Puriﬁed CD4þ T cells obtained during the clinical response to DLI were stimulated with HeLa-II cells transduced with donor- or
patient-speciﬁc HLA-DPB1 molecules. (A) After 6-18 hours of incubation, intacellular IFN-g (upper panel) or CD154 (lower panel) staining was determined by ﬂow
cytometry. (B) After 16-44 hours of incubation, surface CD137 (upper panel) and CD154 (lower panel) expression was determined by ﬂow cytometry. (C) Percentages
of CD137-expressing CD4þ T cells after incubation with patient HLA-DPB1*03:01 (-), donor HLA-DPB1*04:02 ( ), or medium alone (,) was determined at different
time points. Mean results  SD of 2-4 individual experiments are shown.
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Figure 2. Emergence of patient HLA-DPespeciﬁc CD4þ T cells after HLA-DPB1emismatched allo-SCT and DLI. (A) Percentage of donor chimerism in bone marrow
after allo-SCT. The arrow indicates DLI. Conversion to 100% donor chimerism was observed 3 months after DLI. (B) CD4þ T cells puriﬁed from donor PBMNCs, patient
PBMNCs obtained after allo-SCT before DLI, and 6 weeks after DLI were stimulated with HeLa-II cells, HeLa-II cells transduced with donor HLA-DPB1*05:01 or shared
HLA-DPB1*04:01, HeLa-II cells transduced with patient HLA-DPB1*01:01, or left unstimulated. Percentages of CD137-expressing CD4þ T cells after 44 hours of
incubation are shown.
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patients (patients 8 and 9), low percentages of HLA-
DPespeciﬁc CD4þ T cells were also measured after allo-SCT
before DLI (0.16% and 0.25%, respectively).
In summary, in 14 of 24 (58%) patient-donor combinations
analyzed, patient HLA-DPespeciﬁc CD4þ/CD137þ T cells were
found, indicating that HLA-DPespeciﬁc CD4þ T cell responses
frequently occurred after HLA-DPB1emismatched allo-SCT
and DLI.
Clinical Responses after HLA-DPB1eMismatched
T CelleDepleted Allo-SCT and DLI
We evaluated whether the presence of patient HLA-
DPespeciﬁc CD4þ T cells after HLA-DPB1emismatched
T celledepleted allo-SCT and DLI was related to clinical
outcome. Clinical responses to DLI were deﬁned as beneﬁcial
clinical responses or GVHD. A clinical response to at least 1 of
the DLIs was observed in 18 of 24 patients (75%). Both a bene-
ﬁcial clinical response and GVHD were observed in 5 patients
(Table 1, patients 1-5). Three patients (patients 6-8) developed
GVHD without a beneﬁcial clinical response, and 10 patients
(patients 9-18) demonstrated selective beneﬁcial responses
without GVHD. The remaining 6 patients (patients 19-24)
showed no clinical response to DLI.
Figure 4A shows the percentages of patient HLA-
DPespeciﬁc CD137þ/CD4þ T cells for patients with and
without a clinical response after DLI. Patient HLA-
DPespeciﬁc CD4þ T cells were seen in 13 of 18 patients
(72%) with a clinical response after DLI and in only 1 of 6
patients (17%) without a clinical response after DLI. The latter
patient (patient 24) suffered from lymphoma and died due to
progressive disease at 4 months after DLI. These results
illustrate an association between the presence of patientHLA-DPespeciﬁc CD4þ T cells and the development of clin-
ical responses after DLI (P ¼ .05).
Figure 4B shows the percentages of patient HLA-
DPespeciﬁc CD137þ/CD4þ T cells in patients with GVHD after
DLI and patients with selective beneﬁcial clinical responses.
CD137þ/CD4þ T cells were detected in all patients with GVHD
(patients 1-8) and in 5 of the 10 patients with selective bene-
ﬁcial clinical responses (patients 9-13). These data illustrate an
association between the presence of patient HLA-DPespeciﬁc
CD4þ T cells and the development of clinical signiﬁcant GVHD
(P ¼ .036). However, patient HLA-DPespeciﬁc CD4þ T cells
were also found in patients with selective GVL responses.
Permissive and Nonpermissive HLA-DPB1 Mismatches
To determine whether patient HLA-DPespeciﬁc CD4þ
T cells were preferentially found in nonpermissive mismatch
combinations compared with permissive mismatch combi-
nations [19,22], we analyzed the percentages of CD137þ/
CD4þ T cells found after allo-SCT and DLI in these 2 groups.
Nine patients had 2 mismatched HLA-DPB1 alleles in the
GVH direction. We analyzed each mismatched HLA-DPB1
allele separately. In total 19 permissive HLA-DPB1
mismatches and 14 nonpermissive HLA-DPB1 mismatches
were present (Supplemental Table S1). Figure 5 shows the
percentages of CD137þ/CD4þ T cells in each category. Patient
HLA-DPespeciﬁc CD4þ T cells were found in both permissive
and nonpermissive mismatched combinations, showing a
slightly higher median percentage in the nonpermissive
group (P ¼ .22).
DISCUSSION
We have developed an assay to screen patients for HLA-
DPespeciﬁc immune responses after HLA-DPB1emismatched
Figure 3. HLA-DPespeciﬁc CD137þ/CD4þ T cells observed after HLA-
DPB1emismatched allo-SCT and DLI in 24 individuals. A total number of 24
patientedonor combinations were analyzed for the presence of patient HLA-
DPespeciﬁc CD4þ T cells. In total, percentages of CD137þ/CD4þ T cells in
response to 39 donor or shared HLA-DPB1 molecules and 33 patient-speciﬁc
HLA-DPB1 molecules are shown. For each patientedonor combination, CD4þ
T cells puriﬁed from donor PBMNCs and patient PBMNCs obtained after allo-
SCT before DLI and after DLI were stimulated with HeLa-II cells transduced
with donor or shared HLA-DPB1 molecules (B) or HeLa-II cells transduced
with patient-speciﬁc HLA-DPB1 molecules (C). Percentages of CD137þ/CD4þ
T cells are shown after 44 hours of coincubation with Hela-II cells. Results were
corrected for background CD137 expression on unstimulated CD4þ T cells. For
each patientedonor combination, representative results obtained after only
1 DLI are shown. HLA-DPespeciﬁc immune responses were deﬁned as
detection of >0.15% CD137þ/CD4þ T cells after stimulation with Hela-II cells
transduced with patient-speciﬁc HLA-DPB1 molecules based on <0.10%
CD137þ/CD4þ T cells in response to donor-speciﬁc or shared HLA-DPB1
molecules. The line represents the threshold of 0.15% for positive results.
Results post-DLI represent the ﬁrst DLI except for patients 14, 15, and 17.
Results to the ﬁrst DLI with a clinical response are shown for these patients.
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Figure 4. HLA-DPespeciﬁc CD137þ/CD4þ T cells in patients with and without
clinical responses to DLI. Percentages of CD137þ/CD4þ T cells in response to
stimulation with HeLa-II cells transduced with patient HLA-DPB1 molecules
obtained after allo-SCT and DLI are shown. Results were corrected for back-
ground CD137 expression on unstimulated CD4þ T cells. For 9 patients who
were screened for CD4þ T cells speciﬁc for 2 different patient-speciﬁc HLA-
DPB1 molecules, results for only 1 HLA-DPB1 molecule with the highest
percentage of CD137þ/CD4þ T cells are depicted. (A) Patient HLA-DPespeciﬁc
CD4þ T cells were found in 13 of 18 patients with clinical responses to DLI and
in 1 of 6 patients without clinical responses to DLI. (B) CD137þ/CD4þ T cells
were found in all 8 patients with GVHD (in presence or absence of GVL), and in
5 of 10 patients who developed beneﬁcial clinical responses without GVHD
(selective GVL reactivity). CD137þ/CD4þ T cells were detected in only 1 patient
without clinical response to DLI.
C.E. Rutten et al. / Biol Blood Marrow Transplant 19 (2013) 40e4846T celledepleted allo-SCT and DLI. Using HeLa cells trans-
duced with various genes encoding relevant molecules for
appropriateHLAclass II processing in conjunctionwithdifferent
HLA-DPmolecules as stimulator cells, wewere able to measure
the emergence of patient HLA-DPespeciﬁc CD4þ T cells in
PB in a simple and effective manner. In our study cohort,
patient HLA-DPespeciﬁc CD4þ Tcell responseswere frequently
found after HLA-DPB1emismatched DLI (58%). The presence of
HLA-DPespeciﬁc CD4þ Tcells correlatedwith clinical responses
to DLI, because patient HLA-DPespeciﬁc CD4þ T cells were
detected in 13 of 18 patients (72%)with clinical responses to DLI
but in only 1 of 6 patients (17%) without clinical responses (P¼
.05).HLA-DPespeciﬁcCD4þTcellsweremostdominantly found
in patients who developed GVHD, but patient HLA-DPespeciﬁc
CD4þ Tcells were also found in a signiﬁcant number of patients
whodevelopedbeneﬁcial clinical responseswithoutGVHDafter
DLI. HLA-DPespeciﬁc CD4þ T cell responses were induced in
patients suffering from a variety of hematologic malignancies,
including multiple myeloma, B cell malignancies, and myeloid
leukemias.
Since alloreactive T cells recognizing mismatched HLA
alleles are present in relatively high frequencies in PB [23],
HLA-mismatched allo-SCT is likely to frequently induce
alloimmune responses. Our study indeed demonstrates that
mismatching for HLA-DPB1 frequently resulted in the
generation of patient HLA-DPespeciﬁc immune responses. In
the majority of patients, HLA-DPespeciﬁc CD4þ T cells were
not found in patient PBMNCs obtained before DLI, indicating
de novo induction of HLA-DPespeciﬁc Tcell responses byDLI.
Moreover, the high frequencies of patient HLA-DPespeciﬁc
T cells after DLI reﬂected in vivo development andexpansion of an antieHLA-DP response in the patients, since
in only 2 cases low frequencies of patient HLA-DPespeciﬁc
CD4þ T cells could directly be detected in donor PBMNC.
In this study, GVHD was associated with the presence of
patient HLA-DPespeciﬁc CD4þ T cells. In the majority of
patients, GVHD coincided with a beneﬁcial clinical response;
however, patient HLA-DPespeciﬁc CD4þ T cells were also
found in patients with selective GVL reactivity without
GVHD, illustrating that HLA-DPespeciﬁc CD4þ T cells may
induce GVL responses in the presence or absence of GVHD.
HLA-DPB1emismatched allo-SCT may induce selective
GVL reactivity without GVHD, since constitutive expression
of HLA class II molecules is mainly restricted to
hematopoietic cells. However, HLA class II expression on
various tissues can be up-regulated after exposure to
proinﬂammatory cytokines. An HLA-DPespeciﬁc immune
response may result in GVHD if HLA class II molecules on
nonhematopoietic tissues are up-regulated as a consequence
of conditioning regimens, infections, or ongoing immune
responses. In some of the patients with GVHD, a pro-
inﬂammatory environment might have been induced by
non-permissive permissive
%
C
D
1
3
7
+
/ C
D
4
+
 
T
-
c
e
l
l
s
0.01
0.1
1
10
Figure 5. HLA-DPespeciﬁc CD137þ/CD4þ T cells in response to permissive and
nonpermissive mismatches. Percentages of CD137þ/CD4þ T cells in response to
stimulation with HeLa-II cells transduced with patient HLA-DPB1 molecules
obtained after allo-SCT and DLI are shown. Results were corrected for back-
ground CD137 expression on unstimulated CD4þ T cells. CD137þ/CD4þ T cell
responses to each HLA-DPB1 allele are depicted separately. The modiﬁed
algorithm classifying HLA-DPB1 alleles in 4 categories was used [19]. Results of
nonpermissive and permissive HLA-DPB1 mismatch combinations are shown.
The horizontal line represents median values.
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Alternatively, a profound HLA-DPespeciﬁc GVL response
might have induced proinﬂammatory cytokines, resulting in
up-regulation of HLA class II molecules on nonhematopoietic
cells, thereby inducing GVHD. Furthermore, both GVHD and
GVL reactivity might have been mediated by the simulta-
neous development of immune responses directed against
molecules other than HLA-DP. An inﬂammatory environment
induced byminor histocompatibility antigen (MiHA)-speciﬁc
CD4þ or CD8þ T cell responses [4,6,24-27] may have
provoked or enhanced HLA-DPespeciﬁc immune responses.
Because HLA-DPespeciﬁc CD4þ T cells were found both in
the presence and absence of GVHD, it is likely that the
development of GVHD is not solely determined by the
induction of an HLA-DPespeciﬁc immune response, but also
by other immune responses and factors inﬂuencing HLA class
II expression on nonhematopoietic cells.
Antigen-presenting cells are required for efﬁcient induc-
tion of antitumor immunity in vivo. In this study,
HLA-DPespeciﬁc CD4þ T cells were found in patients with
relapsed or persistent disease, as well as in patients who
received DLI for mixed chimerism. In patients with relapsed
or persistent disease, malignant cells with sufﬁcient HLA-DP
expression may have served as antigen-presenting cells to
induce HLA-DPespeciﬁc immune responses. Alternatively,
crosstalk between CD4þ T cells and leukemic cells may have
induced an antigen-presenting cell phenotype on leukemic
cells, thereby amplifying HLA class IIespeciﬁc immune
responses [28]. In other patients, residual patient-derived
hematopoietic cells may have served as APCs to induce
HLA-DPespeciﬁc CD4þ T cell responses. Previous in vitro
studies have demonstrated that HLA-DPespeciﬁc CD4þ
T cells were capable of recognizing and lysing multiple
myeloma cells, B cell malignancies and myeloid leukemic
cells with sufﬁcient HLA-DP expression [5,17,29,30]. Based on
these in vitro experiments, HLA-DPespeciﬁc CD4þ T cells are
expected to induce antitumor reactivity against a variety of
hematologic malignancies in vivo. Indeed, in our study
beneﬁcial clinical responses after HLA-DPB1emismatched
allo-SCT and DLI were found in patients suffering frommultiple myeloma, various B cell malignancies, and myeloid
leukemia.
In this study, 6 patients did not respond to DLI. Two
patients had progressive disease at the time of DLI. In 1 of
these patients, HLA-DPespeciﬁc CD4þ Tcells were found, but
this patient died too early to beneﬁt from the treatment. The
other patient suffered from acute myeloid leukemia, and
immunotolerizing effects might have hindered the induction
of an immune response. In 3 patients, DLIwas administered at
99% donor chimerism. It is likely that in these patients, the
numbers of patient-derived HLA class IIeexpressing APCs
were insufﬁcient to induce an HLA-DPespeciﬁc immune
response. Accordingly, levels of patient chimerism did not
change over time, reﬂecting a stable clinical situation in these
patients. In the last patient, mixed chimerism did not convert
to 100% donor chimerismwithin 6 months after DLI.
In 5 patients with a selective beneﬁcial response to DLI,
no HLA-DPespeciﬁc CD4þ T cells were detected in samples
available for analysis. Two patients (patients 14 and 15)
received other treatments in the period duringwhichDLIwas
given. One patient received several drugs for multiple
myeloma in combinationwith multiple DLIs, ﬁnally resulting
in a sustained complete remission. The other patient received
Rituximab and prednisone for repeated episodes of autoim-
mune hemolytic anemia and thrombocytopenia. In both
patients, the speciﬁc contributionof eachdrugor treatment to
the clinical response could not be identiﬁed, and the other
treatments are likely to have hampered the analysis of HLA-
DPespeciﬁc CD4þ T cells.
The other 3patients (patients 16-18)were treatedwithDLI
for minimal residual disease as illustrated by molecular or
cytogenetic, but nohematologic, relapse. Byclonal isolationof
activated CD4þ T cells, we detected low numbers of patient
HLA-DPespeciﬁc CD4þ T cells in all 3 patients (4%-20% of
expanded CD4þ T cell clones; data not shown). In these
patients, the overall percentages of patient HLA-DPespeciﬁc
CD4þ T cells were below the threshold of sensitivity of our
screening method (0.10%). Because we could not unequivo-
cally demonstrate that these HLA-DPespeciﬁc CD4þ T cells
contributed to clinical responses, we did not score them as
positive results. However, even considering these responses
as negative, our statistical analysis revealed a signiﬁcant
correlation between the presence of HLA-DPespeciﬁc CD4þ
T cells and the development of clinical responses. Alterna-
tively, we may have missed a signiﬁcant response if PBMCs
were not collected at the optimal moment during immune
responses. We previously demonstrated for MiHA-speciﬁc
CD8þ T cells, peak responses may not persist longer than 2
weeks [4,6,31,32]. Studying thekinetics of CD4þTcells ismore
difﬁcult owing to the lack of HLA class II tetramers, but several
studies showed long-term persistence of alloreactive CD4þ T
cells [5,27,33]. Alternatively, some patients might have had
immune responses directed toward other mismatched anti-
gens, including MiHAs. Indeed, in 2 of these patients, we
successfully isolated low frequencies ofMiHA-speciﬁc CD8þ T
cell clones after DLI (data not shown).
In conclusion, this study has demonstrated that HLA-
DPespeciﬁc CD4þ T cells are frequently present in patients
treated with T celledepleted HLA-DPB1emismatched allo-SCT
andDLI for varioushematologicmalignancies.HLA-DPespeciﬁc
CD4þ T cells were found in patients with beneﬁcial clinical
responses in both the presence and absence of GVHD. It is likely
that local environmental circumstances and induction of other
immune responses may determine the balance between GVHD
and GVL reactivity in each individual. To investigate more
C.E. Rutten et al. / Biol Blood Marrow Transplant 19 (2013) 40e4848speciﬁcally the effect of HLA class IIemediated immune
responses on GVL reactivity and GVHD, a randomized clinical
study analyzing the effect of puriﬁed CD4þ DLI early after
transplantationondonorchimerism,disease relapse, andGVHD
is currently ongoing in our center.
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